Carbamazepine (Tegretol CR 400 mg) and Upadacitinib: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Strong CYP3A4 induction can reduce upadacitinib exposure and treatment response.
Clinical significance and safety
Tegretol CR 400 mg contains a strong CYP3A4 inducer. It can reduce upadacitinib exposure and effectiveness; the prescribing information does not recommend this combination. The treating team should assess alternatives without the patient independently stopping either medicine.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.